The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia

  • J. K. H. Rees
  • R. Gray
  • F. G. J. Hayhoe
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

The Ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia (AML) opened in February 1984 to all patients with primary or secondary forms of the disease; there was no age limit. Patients were randomised to receive either a 1 + 5 DAT combination (daunorubicin 50 mg/m2 i.v. on day 1, cytosine arabinoside 100 mg/m2 i.v. every 12 h on days 1–5, and 6-thioguanine 100 mg/m2 every 12 h on days 1–5) or a 3 +10 DAT regime (daunorubicin at the same dose on days 1, 3, and 5 and cytosine arabinoside and 6-thioguanine again at the same doses as in the 1 + 5 combination but on days 1–10).

Keywords

Leukemia Cyclophosphamide Prednisolone Etoposide Cytosine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • J. K. H. Rees
    • 1
  • R. Gray
    • 2
  • F. G. J. Hayhoe
    • 1
  1. 1.Departments of Haematological MedicineUniversity of Cambridge Clinical SchoolCambridgeEngland
  2. 2.Departments of Cancer StudiesUniversity of OxfordOxfordEngland

Personalised recommendations